Literature DB >> 33512616

Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain.

Ana Fuentes1, Esther Serrano-Conde1, Carolina Roldán2, Rafael Benito-Ruesca3, Gregoria Mejías4, Antonio Sampedro5, Gabriel March-Roselló6, Isabel Fernández-Natal7, Juliana Esperalba8, Mario José Rodríguez9, Paula Martínez de Aguirre10, Carlos Salas11, María Lourdes Roc12, Luis Miguel Soria13, Mónica Parra-Grande14, María Dolores Montero15, Ricardo Fernández-Roblas16, Francisco Franco-Álvarez de Luna17, Carmen Lozano18, Federico García19.   

Abstract

AIM: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic.
METHODS: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
RESULTS: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
CONCLUSION: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.

Entities:  

Keywords:  COVID-19; Diagnosis; IgA; IgG; IgM; SARS-COV-2

Year:  2021        PMID: 33512616      PMCID: PMC7843881          DOI: 10.1007/s10096-020-04139-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  2 in total

1.  Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2.

Authors:  Wanbing Liu; Lei Liu; Guomei Kou; Yaqiong Zheng; Yinjuan Ding; Wenxu Ni; Qiongshu Wang; Li Tan; Wanlei Wu; Shi Tang; Zhou Xiong; Shangen Zheng
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

2.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection.

Authors:  Victor M Corman; Ali M Albarrak; Ali Senosi Omrani; Mohammed M Albarrak; Mohamed Elamin Farah; Malak Almasri; Doreen Muth; Andrea Sieberg; Benjamin Meyer; Abdullah M Assiri; Tabea Binger; Katja Steinhagen; Erik Lattwein; Jaffar Al-Tawfiq; Marcel A Müller; Christian Drosten; Ziad A Memish
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

  2 in total
  2 in total

1.  Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon.

Authors:  Gabriella S Oliveira; Luciana Silva-Flannery; Juliana F Silva; Charlene Siza; Roberto J Esteves; Barbara J Marston; Juliette Morgan; Mateusz Plucinski; Tárcio P Roca; Ana M P Silva; Soraya S Pereira; Juan M V Salcedo; Dhelio B Pereira; Felipe G Naveca; Deusilene S Vieira Dall'Acqua
Journal:  J Med Virol       Date:  2022-03-22       Impact factor: 20.693

2.  Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.

Authors:  Laura Serrano; Sonia Algarate; Beatriz Herrero-Cortina; Jessica Bueno; María T González-Barriga; María Ducons; Jesica Montero-Marco; Beatriz Acha; Ana Taboada; Pilar Sanz-Burillo; Cristina Yuste; Rafael Benito
Journal:  J Appl Microbiol       Date:  2022-07-18       Impact factor: 4.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.